Analyst Price Targets — ACRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 30, 2026 12:09 pm | Adam Vogel | Craig-Hallum | $10.00 | $3.43 | TheFly | Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy |
| November 19, 2024 7:35 am | Julian Harrison | BTIG | $8.00 | $3.14 | StreetInsider | BTIG Upgrades Aclaris Therapeutis (ACRS) to Buy |
| November 19, 2024 7:34 am | Roger Song | Jefferies | $7.00 | $3.14 | StreetInsider | Jefferies Upgrades Aclaris Therapeutis (ACRS) to Buy |
| November 6, 2024 5:46 pm | Alex Thompson | Stifel Nicolaus | $3.00 | $2.28 | StreetInsider | Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel |
| December 1, 2022 5:35 am | — | Goldman Sachs | $25.00 | $15.22 | Benzinga | Goldman Sachs Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $25 |
Latest News for ACRS
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.1 per share a year ago.
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - -…
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial of ATI-052, the Company's potential best-in-class investigational bispecific anti-TSLP/IL-4Rα antibody, in…
Pre-Market Stock Futures: Futures are trading lower as we prepare to close out the trading week. What a difference a day can make. After a blockbuster rally on Wednesday, the stock market reversed course and sold off on Thursday, and that could carry over into today. While the major indices ended off their midday lows,... Here Are Friday's Top Wall Street Analyst Research Calls: Broadcom, Circle Internet, Kenvue,…
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACRS.
U.S. House Trading
No House trades found for ACRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.